维生素E醋酸酯(Vitamine E Acetate)

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

神经系统疾病心血管疾病消化系统疾病+ [4]

在研适应症-

非在研适应症

非胰岛素依赖型糖尿病22型糖尿病血脂障碍+ [16]

原研机构-

在研机构-

非在研机构

Hospital General Universitario de Elche

Technion-Israel Institute of TechnologyDSM Nutritional Products AG

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与维生素E醋酸酯相关的临床试验

NCT03765827 / Completed临床3期IIT

Effect of the Application of Vitamin E Ointment, Over Staple Lines and Anastomosis in Roux-en-Y Gastric Bypass, on Postoperative Pain

Patients will be randomized into 2 groups:
Vit E group: Vitamin E ointment will be applied over staple lines and anastomoses
Control group: Vitamin E will not be applied
Postoperative pain will be assessed 24 hours after surgery.

开始日期2018-12-05

申办/合作机构

Hospital General Universitario de Elche

NL-OMON47088 / CompletedN/AIIT

VITAMINE: The effectiveness of a tablet computer supported home-based exercise training program and optimal protein intake in community dwelling older adults to improve physical functioning; a randomized controlled trial - VITAMINE

开始日期2016-03-24

申办/合作机构-

IRCT2016062528617N1 / Completed临床2/3期IIT

The effects of Multi Minerals (Zn, Mg and Ca) and Vitamins (C and E) Supplementation in the Prevention of Preeclampsia

开始日期2015-03-16

申办/合作机构

Medical University of Ilam

100 项与维生素E醋酸酯相关的临床结果

登录后查看更多信息

100 项与维生素E醋酸酯相关的转化医学

登录后查看更多信息

100 项与维生素E醋酸酯相关的专利（医药）

登录后查看更多信息

226

项与维生素E醋酸酯相关的文献（医药）

2024-11-01·Journal of Obstetrics and Gynaecology Canada

The Association of Vitamin D with Uterine Fibroids in Premenopausal Patients: A Systematic Review and Meta-Analysis

Review

作者: Pudwell, Jessica ; Ivanova, Marina ; Bougie, Olga ; Soule, Allison

OBJECTIVEThis study aims to consolidate existing literature regarding the association between vitamin D and uterine fibroid presence and growth.DATA SOURCESA comprehensive search across databases including Medline, Embase, CINAHL, Web of Science, ClinicalTrials.gov, and grey literature was conducted from inception to February 2023, using relevant keywords. Authors were contacted for unpublished data.STUDY SELECTIONFrom 9931 studies screened based on title and abstract, those evaluating serum vitamin D levels or vitamin D treatment effects, using ultrasonography for diagnosis, and involving at least 25 premenopausal participants were included. Case reports, case series, and reviews were excluded.DATA EXTRACTION AND SYNTHESISData were extracted using a predefined form. Methodological quality was assessed through the Newcastle-Ottawa Scale and the Risk of Bias-2 tools. Evidence quality was evaluated using Grading of Recommendations Assessment, Development, and Evaluation. Data from 3 randomised controlled trials (n = 328) and 23 observational studies (n = 5650) were meta-analyzed via random-effects modelling. Patients receiving oral vitamin D supplementation had a significantly different change in fibroid size (standardized mean difference -5.7%; CI -10.63 to -0.76, P = 0.02, I² = 99%), as measured by the percentage change in diameter or volume, compared to controls, over the span of 2-6 months. Those receiving supplementation had vitamin D insufficiency; regimens varied between 50 000 IU weekly for 12 weeks, 50 000 IU weekly for 8 weeks, and 50 000 IU biweekly for 10 weeks. Patients with fibroids exhibited lower serum vitamin D concentrations (mean difference -5.50 ng/mL; CI 6.99 to -4.01, P < 0.001, I² = 87%) and higher odds of vitamin D deficiency (OR 3.71; CI 1.90-7.24, P < 0.001, I² = 80%).CONCLUSIONThis review underscores the potential of vitamin D in mitigating fibroid development and growth. While promising, further research is warranted to optimise dosage and treatment duration, potentially offering a non-invasive solution for at-risk patients. Continued exploration of vitamin D's role in fibroid treatment is encouraged.

2024-08-01·Journal of Obstetrics and Gynaecology Canada

The Association of Vitamin D with Uterine Fibroids in Premenopausal Patients: a Systematic Review and Meta-Analysis

Review

作者: Pudwell, Jessica ; Ivanova, Marina ; Bougie, Olga ; Soule, Allison

OBJECTIVEThis study aims to consolidate existing literature regarding the association between vitamin D and uterine fibroid presence and growth.DATA SOURCESA comprehensive search across databases including MEDLINE, Embase, CINAHL, Web of Science, ClinicalTrials.gov, and grey literature was conducted from inception to February 2023, using relevant keywords. Authors were contacted for unpublished data.STUDY SELECTIONFrom 9931 studies screened based on title and abstract, those evaluating serum vitamin D levels or vitamin D treatment effects, using ultrasonography for diagnosis, and involving at least 25 pre-menopausal participants were included. Case reports, case series, and reviews were excluded.DATA EXTRACTION AND SYNTHESISData were extracted using a predefined form. Methodological quality was assessed through the Newcastle-Ottawa Scale and the Risk of Bias-2 tools. Evidence quality was evaluated using Grading of Recommendations Assessment, Development, and Evaluation. Data from three randomized controlled trials (n = 328) and 23 observational studies (n = 5650) were meta-analyzed via random effects modeling. Patients receiving oral vitamin D supplementation had a significantly different change in fibroid size (SMD -5.7%, CI -10.63 to -0.76, P = 0.02, I2 = 99%), as measured by percentage change in diameter or volume, compared to controls, over the span of 2-6 months. Those receiving supplementation had vitamin D insufficiency; regimens varied between 50 000 IU weekly for 12 weeks, 50 000 IU weekly for 8 weeks, and 50 000 IU biweekly for 10 weeks. Patients with fibroids exhibited lower serum vitamin D concentrations (MD -5.50 ng/mL, CI 6.99 to -4.01, P < 0.001, I2 = 87%) and higher odds of vitamin D deficiency (OR 3.71, CI 1.90-7.24, P < 0.001, I2 = 80%).CONCLUSIONThis review underscores the potential of vitamin D in mitigating fibroid development and growth. While promising, further research is warranted to optimize dosage and treatment duration, potentially offering a non-invasive solution for at-risk patients. Continued exploration of vitamin D's role in fibroid treatment is encouraged.OBJECTIFCette étude vise à consolider la littérature existante concernant l'association entre la vitamine D et la présence et la croissance des fibromes utérins. SOURCE DES DONNéES: Une recherche exhaustive a été réalisée dans les bases de données MEDLINE, Embase, CINAHL, Web of Science et ClinicalTrials.gov et dans la littérature à l'aide de mots-clés pertinents pour la période allant de leur création à février 2023. Les auteurs ont été contactés pour obtenir des données non publiées. SéLECTION DES éTUDES: Dans les 9 931 études sélectionnées d'après leurs titre et résumé, seules celles ayant évalué les taux sériques de vitamine D ou les effets d'un traitement à la vitamine D, utilisé l'échographie pour le diagnostic et comptant au moins 25 participantes non ménopausées ont été retenues. Les études de cas, les études de série de cas et les revues n'ont pas été retenues. EXTRACTION DES DONNéES ET SYNTHèSE: Les données ont été extraites au moyen d'un formulaire prédéfini. La qualité méthodologique a été évaluée au moyen de l'échelle de Newcastle-Ottawa et de l'outil d'évaluation du risque de biais RoB-2. La qualité des données a été évaluée à l'aide de la méthodologie GRADE (Grading of Recommendations, Assessment, Development, and Evaluation). Les données de trois essais cliniques randomisés (n = 328) et de 23 études observationnelles (n = 5650) ont été méta-analysées à l'aide d'une modélisation à effets aléatoires. Les patientes recevant une supplémentation orale en vitamine D ont présenté un changement significativement différent de la taille des fibromes (différence des moyennes standardisées : -5,7 %; IC : -10,63 à -0,76; P = 0,02; I2 = 99 %), tel que mesuré par le changement en pourcentage du diamètre ou du volume, par rapport aux témoins, sur une période de 2 à 6 mois. Les personnes recevant une supplémentation présentaient une insuffisance en vitamine D; les schémas posologiques étaient de 50 000 UI par semaine pendant 12 semaines, 50 000 UI par semaine pendant 8 semaines ou 50 000 UI toutes les deux semaines pendant 10 semaines. Les patientes atteintes de fibromes avaient des concentrations sériques de vitamine D plus faibles (différence moyenne : -5,50 ng/mL; IC : 6,99 à -4,01; P < 0,001; I2 = 87 %) et un risque plus élevé de carence en vitamine D (RC : 3,71; IC : 1,90-7,24; P < 0,001; I2 = 80 %).CONCLUSIONCette étude souligne le potentiel de la vitamine D dans l'atténuation du développement et de la croissance des fibromes. Bien que ces conclusions soient prometteuses, la recherche doit se poursuivre afin d'optimiser le dosage et la durée du traitement, ce qui pourrait constituer une solution non invasive pour les patientes à risque. La poursuite de l'étude du rôle de la vitamine D dans le traitement des fibromes est encouragée.

2024-04-15·Current Pediatric Reviews

Effects of Vitamin D and E Supplementation on Prevention of Bronchopulmonary Dysplasia (BPD) in Premature Neonates: A Systematic Review and Meta-Analysis

Article

作者: Yaghoobpoor, Shirin ; Ahsan, Elahe ; Fatahi, Somaye ; Sharma, Deepak ; Vakili, Kimia ; Deravi, Niloofar ; Fathi, Mobina ; Farahbakhsh, Nazanin ; Tutunchian, Zohreh ; Tabatabaii, Seyed Ahmad

Background:Bronchopulmonary Dysplasia (BPD) has a multifactorial etiology. Vitamin E and vitamin D play an important role in lung development and can potentially be beneficial in the prevention of BPD.Objective:The study aimed to compare the risk of BPD occurrence in preterm neonates supplemented with vitamin D or E versus those who did not get supplementation.Methods:The literature search was conducted for this systematic review by searching the PubMed, Scopus, and Web of Science databases up to December 2022. Randomized controlled trials involved administering vitamin D or E to preterm neonates and examining the occurrence of BPD. We excluded non-English articles, and articles with non-relevant and insufficient data. We used the Critical Appraisal Skills Programme (CASP) checklist to assess the quality of the included studies. We used Egger’s test to evaluate the risk of bias among the included studies. Heterogeneity was also assessed through Q-test and I2. We applied the random effect model for analysis. A P-value less than 0.05 was considered as significant. All the statistical analysis in the current study was performed using STATA 14. The Relative Risk (RR) was calculated as the effect size with 95% Confidence Interval (CI).Results:Three eligible studies seeking the role of vitamin D in the prevention of BPD were analysed. Meta-analysis revealed that receiving vitamin D supplementation can significantly reduce the risk of BPD in preterm infants (RR = 0.357, 95% CI: 0.189-0.675, I2 = 0.0%; p = 0.002). Similarly, for assessing the role of Vitamin E in the prevention of BPD, three eligible studies were analysed. Vitamin E supplementation was not found to play a significant role in the reduction of BPD (RR = 0.659, 95%CI = 0.243-1.786, I2 = 38.7%; p = 0.412).Conclusion:Vitamin D supplementation could be beneficial in preventing BPD in preterm infants. However, evidence is not enough regarding vitamin E's role in reducing the incidence of BPD in preterm infants.

100 项与维生素E醋酸酯相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
纤维化	临床3期	美国	DSM Nutritional Products AG	2020-01-03
遗传病	临床3期	美国	DSM Nutritional Products AG	2020-01-03
肝硬化	临床3期	美国	DSM Nutritional Products AG	2020-01-03
维生素E缺乏症	临床3期	美国	DSM Nutritional Products AG	2020-01-03
术后疼痛	临床3期	西班牙	Hospital General Universitario de Elche	2018-12-05
非胰岛素依赖型糖尿病2	临床3期	以色列	Technion-Israel Institute of Technology	2009-01-31
遗传性胰腺炎	临床3期	以色列	Technion-Israel Institute of Technology	2009-01-31
心肌梗塞	临床3期	以色列	Technion-Israel Institute of Technology	2009-01-31
休克	临床3期	以色列	Technion-Israel Institute of Technology	2009-01-31
脑卒中	临床3期	以色列	Technion-Israel Institute of Technology	2009-01-31